This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer -- and Why It's a Flawless Safe-Haven for Retirees

Pfizer is undergoing its biggest reinvention in a generation, anchored by the Seagen oncology platform and the recently closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses. With shares near $25.60 and a dividend yield close to 7%, investors are focused on whether the payout is sustainable. Adjusted EPS of $3.22 supports a $1.72 quarterly dividend, about 53% of earnings. Free cash flow totaled $9.08 billion in 2025 after $11.7 billion in operating cash flow and $2.6 billion in capex, while $9.77 billion was paid in dividends, leaving a slender cushion. FCF coverage slipped to 0.93x in 2025 from 1.03x in 2024.